Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Open accessAbstract
Background Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease.Patients and methods We conducted a multi-center phase II trial of sorafenib plus gemcitabine in chemo-naïve patients with histologically-confirmed, advanced pancreatic cancer. Patients received sorafenib 400 mg twice daily and gemcitabine 1,000 mg/m(2) on days 1, 8 and 15 of a 28 day cycle.Results Seventeen patients enrolled at 4 centers; 13 were evaluable for response. There were no objective responses; 18% had stable disease. Median overall survival was 4.0 months (95% CI: 3.4, 5.9); median progression-free survival was 3.2 months (95% CI: 1.6, 3.6). Grade 3/4 toxicities included thrombosis in 18% of patients, dehydration or hand-foot syndrome in 12%, and hypertension or gastrointestinal bleeding in 6%.Conclusion Gemcitabine plus sorafenib is inactive in advanced pancreatic cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Src inhibitors as monotherapy have not yielded promising results.
“To date, Src inhibitors as monotherapy have not yielded promising results [46, 47].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709 · see citing works
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895 · see citing works
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017 · see citing works
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · see citing works
Wilhelm, S. M., Adnane, L., Newell, P. H., Villanueva, A., Llovet, J. M., & Lynch, M. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,462 · see citing works
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914 · see citing works
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848 · see citing works
Self-citationCutsem, E. V., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Laethem, J. V., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J. G. C. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 651 · see citing works
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Kindler, H. L., Friberg, G. R., Singh, D. A., Locker, G. Y., Nattam, S. R., Kozloff, M. F., Taber, D. A., Karrison, T. G., Dachman, A. H., Stadler, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9661 · Cited by 460 · see citing works
Self-citationPoplin, E. A., Feng, Y., Berlin, J. D., Rothenberg, M. L., Höchster, H. S., Mitchell, E. P., Alberts, S. R., O'Dwyer, P. J., Haller, D. G., Catalano, P. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 437 · see citing works
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alavi, A., Hood, J. D., Frausto, R. F., Stupack, D. G., & Cheresh, D. A. (2003) · Science · doi:10.1126/science.1082015 · Cited by 336 · see citing works
Pancreatic cancer and thromboembolic disease
Khorana, A. A., & Fine, R. L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01606-7 · Cited by 269 · see citing works
Spano, J., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H. S., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y. K., Bycott, P. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60661-3 · Cited by 250 · see citing works
Campbell, P. M., Groehler, A. L., Lee, K. M., Ouellette, M. M., Khazak, V., & Der, C. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3752 · Cited by 215 · see citing works
Siu, L. L., Awada, A. H., Takimoto, C. H. M., Piccart, M. J., Schwartz, B. E., Giannaris, T., Lathia, C. D., Petrenciuc, O., & Moore, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1571 · Cited by 188 · see citing works
Hemostatic complications of angiogenesis inhibitors in cancer patients
Elice, F., Jacoub, J., Rickles, F. R., Falanga, A., & Rodeghiero, F. (2008) · American Journal of Hematology · doi:10.1002/ajh.21277 · Cited by 63 · see citing works
Lang, S. A., Schachtschneider, P., Moser, C., Mori, A., Hackl, C., Gaumann, A. K. A., Batt, D. B., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0373 · Cited by 51 · see citing works
Molecular aspects of carcinogenesis in pancreatic cancer.
Koliopanos, A., Avgerinos, C., Paraskeva, C., Touloumis, Z., Kelgiorgi, D., & Dervenis, C. (2008) · PubMed · Cited by 39 · see citing works
Kindler, H. L., & Bylow, K. A. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0018-z · Cited by 32 · see citing works
Self-citationTargeting angiogenesis in pancreatic cancer
Philip, P. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60770-9 · Cited by 14 · see citing works
Iqbal, S. U., Lenz, H., Yang, D. H., Ramanathan, R. K., Bahary, N., Shibata, S., Morgan, R. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11082 · Cited by 5 · see citing works
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316 · see citing works
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170 · see citing works
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 631 · see citing works
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 601 · see citing works
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 589 · see citing works
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 292 · see citing works
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271 · see citing works
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3366 · Cited by 265 · see citing works
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 234 · see citing works
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Chiorean, E. G., & Coveler, A. L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 214 · see citing works
What We Have Learned About Pancreatic Cancer From Mouse Models
Pérez-Mancera, P. A., Guerra, C. E., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 173 · see citing works
Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.255 · Cited by 160 · see citing works
Current concepts and novel targets in advanced pancreatic cancer
Michl, P., & Gress, T. M. (2012) · Gut · doi:10.1136/gutjnl-2012-303588 · Cited by 153 · see citing works
Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells
Jagušt, P., de Luxán‐Delgado, B., Parejo-Alonso, B., & Sancho, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00203 · Cited by 148 · see citing works
Taeger, J., Moser, C., Hellerbrand, C., Mycielska, M. E., Glockzin, G., Schlitt, H. J., Geissler, E. K., Stoeltzing, O., & Lang, S. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0312 · Cited by 144 · see citing works
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
Poh, A., O'Donoghue, R., & Ernst, M. (2015) · OncoTarget · doi:10.18632/oncotarget.4199 · Cited by 121 · see citing works
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
Wöll, S., Schlitter, A. M., Dhaene, K., Roller, M., Esposito, I., Şahin, U., & Türeci, Ö. (2013) · International Journal of Cancer · doi:10.1002/ijc.28400 · Cited by 134 · see citing works
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma
Kondratska, K., Kondratskyi, A., Yassine, M., Lemonnier, L., Lepage, G., Morabito, A., Skryma, R. N., & Prevarskaya, N. B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.02.012 · Cited by 130 · see citing works
Angiogenesis in cancer: Anti-VEGF escape mechanisms.
Prager, G. W., Poettler, M., Unseld, M., & Zielinski, C. C. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.11.02 · Cited by 101 · see citing works
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 101 · see citing works
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 95 · see citing works
Cortés, E., Lachowski, D., Robinson, B. K., Sarper, M., Teppo, J., Thorpe, S. D., Lieberthal, T. J., Iwamoto, K., Lee, D. A., Okada, M., et al. (2018) · EMBO Reports · doi:10.15252/embr.201846557 · Cited by 85 · see citing works
Zhang, Z., Wang, T., Liu, L., & Guo, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090135 · Cited by 77 · see citing works
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 77 · see citing works
Poettler, M., & Prager, G. W. (2011) · Hämostaseologie · doi:10.5482/ha-1163 · Cited by 70 · see citing works
Systemic Chemotherapy in Advanced Pancreatic Cancer
Lee, H. S., & Park, S. W. (2016) · Gut and Liver · doi:10.5009/gnl15465 · Cited by 70 · see citing works
Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis
van Mackelenbergh, M. G., Stroes, C. I., Spijker, R., van Eijck, C. H. J., Wilmink, J. W., Bijlsma, M. F., & van Laarhoven, H. W. M. (2019) · Cancers · doi:10.3390/cancers11050588 · Cited by 60 · see citing works
Zhou, W., Wang, L., Gou, S., Wang, T., Zhang, M., Liu, T., & Wang, C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.033 · Cited by 58 · see citing works
Craven, K. E., Gore, J., & Korc, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.047 · Cited by 56 · see citing works
CXCR2: a target for pancreatic cancer treatment?
Hertzer, K. M., Donald, G. W., & Hines, O. J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772137 · Cited by 53 · see citing works
Cascinu, S., Berardi, R., Sobrero, A. F., Bidoli, P., Labianca, R., Siena, S., Ferrari, D., Barni, S., Aitini, E., Zagonel, V., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.09.020 · Cited by 51 · see citing works
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00331 · Cited by 50 · see citing works
El-Khoueiry, A. B., Ramanathan, R. K., Yang, D., Zhang, W., Shibata, S., Wright, J. R., Gandara, D. R., & Lenz, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9658-9 · Cited by 47 · see citing works
Farran, B., & Nagaraju, G. P. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.07.001 · Cited by 46 · see citing works
Current and future systemic treatment options in metastatic pancreatic cancer.
Arslan, Ç., & Yalçın, Ş. (2014) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.030 · Cited by 44 · see citing works
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
Du, J., Gu, J., & Li, J. (2020) · Bioscience Reports · doi:10.1042/bsr20200401 · Cited by 44 · see citing works
Mattina, J., Carlisle, B. G., Hachem, Y., Fergusson, D. A., & Kimmelman, J. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2000487 · Cited by 40 · see citing works
Pancreatic Cancer from Molecular Pathways to Treatment Opinion
Karanikas, M., Esempidis, A., Chasan, Z. T. M., Deftereou, T.-E., Antonopoulou, M. I., Bozali, F., Amarantidis, K., & Man, Y.-G. (2016) · Journal of Cancer · doi:10.7150/jca.15419 · Cited by 40 · see citing works
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Lue, H.-W., Cole, B. C., Rao, S. A. M., Podolak, J., Gaest, A. V., King, C. J., Eide, C. A., Wilmot, B., Xue, C., Spellman, P. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5971 · Cited by 37 · see citing works
VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis
Georgiadou, D., Sergentanis, T. Ν., Sakellariou, S., Filippakis, G. M., Zagouri, F., Vlachodimitropoulos, D. G., Ψαλτοπούλου, Θ., Lazaris, A. C., Patsouris, E., & Zografos, G. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.01.004 · Cited by 35 · see citing works
Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34 · see citing works
State of the art biological therapies in pancreatic cancer
Marco, M. D. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.55 · Cited by 34 · see citing works
Suri, G. S., Kaur, G., Carbone, G. M., & Shinde, D. A. (2023) · Cancer Reports · doi:10.1002/cnr2.1795 · Cited by 36 · see citing works
Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review
Valsecchi, M., Díaz-Cantón, E., de la Vega, M., & Littman, S. (2013) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-013-9561-z · Cited by 35 · see citing works
Pancreatic cancer: treatment approaches and trends
Pereira, N. P., & Corrêa, J. R. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.13 · Cited by 33 · see citing works
Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines
Alhamdani, M. S. S., Youns, M., Buchholz, M., Gress, T. M., Beckers, M., Maréchal, D., Bauer, A. S., Schröder, C., & Hoheisel, J. D. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.04.042 · Cited by 32 · see citing works
Benckert, C., Thelen, A., Cramer, T., Weichert, W., Gaebelein, G., Gessner, R. V., & Jonas, S. (2011) · Surgery Today · doi:10.1007/s00595-011-0045-0 · Cited by 33 · see citing works
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 31 · see citing works
Pasqualetti, G., Ricciardi, S., Mey, V., Tacca, M. D., & Danesi, R. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.03.003 · Cited by 30 · see citing works
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29 · see citing works
Feng, W., Liu, Y., Bellail, A. C., Olson, J. J., Sun, S. Y., Lu, G., Ding, L., Yuan, C., Wang, G., & Hao, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.005 · Cited by 28 · see citing works
Awasthi, N., Zhang, C., Hinz, S., Schwarz, M. A., & Schwarz, R. E. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-12 · Cited by 28 · see citing works
Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges
Diab, M., Azmi, A. S., Mohammad, R. M., & Philip, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561869 · Cited by 28 · see citing works
Pancreatic cancer from bench to bedside: molecular pathways and treatment options
Kosmidis, C. S., Sapalidis, K. G., Kotidis, E. V., Mixalopoulos, N., Zarogoulidis, P., Tsavlis, D., Baka, S., Man, Y.-G., & Kanellos, J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.11 · Cited by 26 · see citing works
Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Huang, Z. Q., Saluja, A. K., Dudeja, V., Vickers, S. M., & Buchsbaum, D. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796957427 · Cited by 27 · see citing works
Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles
Bhaskar, L. V., Farran, B., Lakkakula, S., Peela, S., Yarla, N. S., Bramhachari, P. V., Kamal, M. A., Saddala, M. S., & Nagaraju, G. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.011 · Cited by 27 · see citing works
Molecular imaging in pancreatic cancer – A roadmap for therapeutic decisions
Krämer-Marek, G., Gore, J., & Korc, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.008 · Cited by 25 · see citing works
BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 25 · see citing works
Targeted therapies in pancreatic cancer: Promises and failures
Bagherabad, M. B., Afzaljavan, F., Shahidsales, S., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26284 · Cited by 24 · see citing works
Brunet, L. R., Hagemann, T., Gaya, A. M., Mudan, S., & Marabelle, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1112942 · Cited by 24 · see citing works
Lee, H. S., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Kim, H. G., Noh, M. H., Lee, S. H., Kim, Y., Kim, H. J., et al. (2017) · Medicine · doi:10.1097/md.0000000000005702 · Cited by 24 · see citing works
Conte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 26 · see citing works
Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor
Yang, H.-H., Liu, J., Lee, J.-H., Harn, H., & Chiou, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158125 · Cited by 22 · see citing works
Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
Blomstrand, H., Batra, A., Cheung, W. Y., & Elander, N. O. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i9.787 · Cited by 19 · see citing works
Park, S., Kim, D., Wu, G. J., Jung, H., Park, J.-A., Kwon, H., & Lee, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186606 · Cited by 19 · see citing works
Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer
Nair, S. T., Abhi, C., Kamalasanan, K., Pavithran, K., Unni, A. R., Sithara, M. S., Sarma, M., & Mangalanandan, T. S. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00801 · Cited by 16 · see citing works
Research advances and treatment perspectives of pancreatic adenosquamous carcinoma
Zhang, W., Zhang, J., Liang, X., & Ding, J. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00732-2 · Cited by 16 · see citing works
Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
Arasanz, H., Hernández, C., Bocanegra, A., Chocarro, L., Zuazo, M., Gato, M., Ausín, K., Santamaría, E., Fernández‐Irigoyen, J., Fernández, G., et al. (2020) · Cancers · doi:10.3390/cancers12082181 · Cited by 14 · see citing works
Liu, Q., Li, R., Wu, H., & Liang, Z. (2023) · BMC Cancer · doi:10.1186/s12885-023-10678-9 · Cited by 14 · see citing works
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 13 · see citing works
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
Spratlin, J. L., & Mulder, K. E. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12095895 · Cited by 12 · see citing works
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
Al-Share, B. A., Hammad, N., & Diab, M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09948-w · Cited by 12 · see citing works
Targeted therapy for pancreatic cancer: lessons learned and future opportunities
Thomas, A. G., & Awasthi, N. (2021) · Digestive Medicine Research · doi:10.21037/dmr-21-21 · Cited by 11 · see citing works
Dorjee, P., & Long, Z.-W. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1433503 · Cited by 11 · see citing works
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy
Collins, D. C., & Morris, P. G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1024654 · Cited by 9 · see citing works
Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma
Lytras, D., Leontara, V., Kefala, M. A., Foukas, P. G., Giannakou, N., Pouliakis, A., Dervenis, C., Panayiotides, I. G., & Karakitsos, P. (2014) · Pancreas · doi:10.1097/mpa.0000000000000197 · Cited by 9 · see citing works
A New Era: Tumor Microenvironment in Chemoresistance of Pancreatic Cancer
Zhao, X., Li, Z., & Gu, Z. (2022) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079146 · Cited by 9 · see citing works
Shukla, S. K., Goyal, M., Kanabar, D. D., Ayehunie, S., Deore, B., Sanhueza, C., Muth, A., & Gupta, V. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124701 · Cited by 8 · see citing works
Wang, Q., Cheng, N., Wang, W., & Bao, Y. (2024) · Cancers · doi:10.3390/cancers16091695 · Cited by 8 · see citing works
An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer
Wang, Q., Wang, J., Yan, H., Li, Z., Wang, K., Kang, F., Tian, J., Zhao, X., & Yun, S. H. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06115-5 · Cited by 7 · see citing works
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Bhattacharya, S., & Rajpurohit, T. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220128161647 · Cited by 6 · see citing works
Trevino, J. G., Verma, M., Singh, S., Pillai, S., Zhang, D., Pernazza, D., Sebti, S. M., Lawrence, N. J., Centeno, B. A., & Chellappan, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0719 · Cited by 6 · see citing works
Prager, G. W., & Zielinski, C. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5857-9_18 · Cited by 6 · see citing works
Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?
Grapsa, D., Saif, M. W., & Syrigos, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.172 · Cited by 6 · see citing works
Tsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5 · see citing works
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers
Kim, E. J.-H., Semrad, T. J., & Bold, R. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1026963 · Cited by 5 · see citing works
Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?
Zimmermann, C., Folprecht, G., Zips, D., Pilarsky, C. P., Saeger, H. D., & Grützmann, R. (2011) · Cancers · doi:10.3390/cancers3022286 · Cited by 3 · see citing works
Mauro, L. A., Herman, J. M., Jaffee, E. M., & Laheru, D. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00081-3 · Cited by 3 · see citing works
Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer
Tang, M., Chen, J., Goldstein, D., Links, M. J., Lord, S. J., Marschner, I. C., Simes, R. J., & Lee, C. K. (2019) · Pancreas · doi:10.1097/mpa.0000000000001429 · Cited by 2 · see citing works
Jesus‐Acosta, A. D., Narang, A. K., Mauro, L. A., Herman, J. M., Jaffee, E. M., & Laheru, D. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00078-5 · Cited by 1 · see citing works
Arasanz, H., Hernández, C., Bocanegra, A., Chocarro, L., Zuazo, M., Gato, M., Ausín, K., Santamaría, E., Fernández‐Irigoyen, J., Fernández, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.01.020446 · Cited by 1 · see citing works
New Targets for Therapy in Pancreatic Cancer
Tinari, N., De, M., Grassadonia, A., Zilli, M., Iacobelli, S., & Natoli, C. (2012) · InTech eBooks · doi:10.5772/27344
Liau, S., & Tuveson, D. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.049
Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer
Malla, S. R., & Gangishetti, U. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_5
Novel Targeted Treatment Approaches in Pancreatic Cancer
Diab, M., Hamid, M. S., Mohammad, R. M., Philip, P. A., & Azmi, A. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_27
Gu, Z., Li, Z.-Z., & Wang, C. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i8.421
Therapy for Metastatic Pancreatic Cancer
Musher, B., & Zhu, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_4
- Authors
- Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E.
- Affiliations
- University of Chicago (US)
- Endeavor Health (US)
- Fort Wayne Medical Institute (US)
- Corresponding author
- Kindler, Hedy Lee
- ORCID
- Venue
- Investigational New Drugs
- Published
- 2010-08-28
- Volume
- 30
- Issue
- 1
- Pages
- 382-386
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- PMC
- PMC4319645
- OpenAlex
- W2061953474
- Cited by
- 103
- References
- 26
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 7 · 2013: 12 · 2012: 9
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01cm62201-16-0-1)
- National Cancer Institute (N01 CM062201, N01 CM-62201)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- gemcitabine, sorafenib, advanced pancreatic cancer, combination chemotherapy, VEGFR-2 inhibition, chemotherapy-naive patients, stable disease, thrombosis, hand-foot syndrome, overall survival, progression-free survival
- MeSH terms
- Sorafenib, Gemcitabine, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzenesulfonates, Chicago, Deoxycytidine, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Niacinamide, Pancreatic Neoplasms, Phenylurea Compounds, Pyridines, Time Factors, Universities, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
